BioSpace News Archive

The Insight Partners published latest research study on “Retinal Imaging Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Device Type (Fluorescein Angiography, Fundus Camera, and Optical Coherence Tomography)

The Insight Partners published latest research study on “Nerve Repair & Regeneration Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product {Neurostimulation & Neuromodulation Devices [Internal Neurostimulation Devices (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, and Gastric Electrical Stimulation)

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at Bernstein’s 39th Annual Strategic Decisions Conference on Thursday, June 1, 2023, at 1:30PM ET.

The Insight Partners published latest research study on ‘Bioinformatics Market Forecast to 2028 - COVID-19 Impact and Global Analysis

The Insight Partners published latest research study on “Neurosurgical Robotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Component [Equipment/System (Robot Machines, Navigation System, Planner & Simulators, and Others), Accessories, and Services]

The Insight Partners published latest research study on “Left Ventricular Assist Device Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028

Vetter, a leading globally operating Contract Development and Manufacturing Organization (CDMO), has been recognized as Best Managed Company for the fourth time in a row – and now carries gold status.

healthŌme™ Inc., a leading genomics-based, health navigation company, today announced its acquisition of Kailos Genetics, LLC, a CLIA-certified and CAP-accredited genetic testing laboratory and supplier of clinical grade laboratory reagents for next-generation sequencing.

Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will acquire Seagen for $229 per share in cash.

PepGen Inc. (Nasdaq: PEPG) today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding their Investigational New Drug Application (IND) to initiate a Phase 1 study of PGN-EDODM1 in patients with Myotonic Dystrophy Type 1 (DM1).